Mirum Pharmaceuticals (MIRM) Projected to Announce Quarterly Earnings on Thursday

Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to issue its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to post earnings of ($0.7279) per share and revenue of $166.0290 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($12.68). The firm had revenue of $159.88 million during the quarter, compared to analyst estimates of $148.21 million. Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The company’s revenue for the quarter was up 43.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.30) earnings per share. On average, analysts expect Mirum Pharmaceuticals to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM opened at $112.23 on Wednesday. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28. The business’s 50 day moving average price is $109.47 and its two-hundred day moving average price is $101.00. The company has a market cap of $6.84 billion, a PE ratio of -8.25 and a beta of 0.48. Mirum Pharmaceuticals has a twelve month low of $50.25 and a twelve month high of $130.00.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, CFO Eric Bjerkholt sold 5,000 shares of the business’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $122.25, for a total transaction of $611,250.00. Following the completion of the transaction, the chief financial officer owned 42,181 shares of the company’s stock, valued at approximately $5,156,627.25. The trade was a 10.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $95.84, for a total value of $2,875,200.00. Following the sale, the chief executive officer owned 194,309 shares of the company’s stock, valued at approximately $18,622,574.56. This represents a 13.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 65,315 shares of company stock worth $6,991,928 over the last three months. Corporate insiders own 8.32% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of MIRM. Janney Montgomery Scott LLC boosted its holdings in shares of Mirum Pharmaceuticals by 6.7% during the 4th quarter. Janney Montgomery Scott LLC now owns 3,200 shares of the company’s stock valued at $253,000 after buying an additional 200 shares in the last quarter. Comerica Bank grew its position in shares of Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after buying an additional 278 shares during the period. Osaic Holdings Inc. increased its stake in shares of Mirum Pharmaceuticals by 46.5% in the 2nd quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock worth $56,000 after acquiring an additional 351 shares in the last quarter. CIBC Private Wealth Group LLC purchased a new position in Mirum Pharmaceuticals during the 4th quarter valued at about $32,000. Finally, The Manufacturers Life Insurance Company lifted its position in Mirum Pharmaceuticals by 2.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,793 shares of the company’s stock valued at $1,160,000 after acquiring an additional 440 shares during the period.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on MIRM. Weiss Ratings lowered Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, June 23rd. Wolfe Research began coverage on shares of Mirum Pharmaceuticals in a research report on Tuesday, May 19th. They set an “outperform” rating and a $145.00 price objective for the company. Citizens Jmp increased their price objective on shares of Mirum Pharmaceuticals from $140.00 to $146.00 and gave the company a “market outperform” rating in a research report on Monday, June 15th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $165.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Finally, TD Cowen increased their price target on shares of Mirum Pharmaceuticals from $125.00 to $145.00 and gave the company a “buy” rating in a report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $143.40.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.